Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make
Until this summer, every approved antibody-drug conjugate held its indication alone. Between 22 May and 31 July, two TROP2-directed conjugates from different owners were approved on both sides of the Atlantic for the same line, in the same disease, in the same patients. The category that has been priced as a set of monopolies just produced its first genuinely contested population, and the two owners are already arguing about which evidence standard should decide it.
- The overlap is exact, not approximate. Datroway was approved in the US on 22 May and in the EU on 31 July; Trodelvy in the EU on 23 June and the US on 24 June. Both are TROP2-directed conjugates carrying topoisomerase-1 payloads. Both are indicated first-line in metastatic triple-negative breast cancer for patients who are not PD-1 or PD-L1 candidates, roughly 70% of that population.
- The evidence packages are not equivalent, and the marketing already says so. Datroway carries overall survival from TROPION-Breast02, a 5.0-month median gain, 23.7 against 18.7 months. Trodelvy’s first-line approvals rest on progression-free survival, a 38% risk reduction in ASCENT-03, with survival data still maturing under a crossover design.
- Trodelvy holds ground Datroway does not. Its US label also covers PD-L1-positive disease at CPS 10 or above in combination with pembrolizumab, so it spans the full first-line population while Datroway competes only in the immunotherapy-ineligible majority.
Substitutability is the event here, not the approvals. A payer facing one conjugate in an indication has no comparator, no reference price and no leverage. A payer facing two, with the same target and the same payload class in the same patients, has all three for the first time in this category. What decides the outcome is not which drug is better but which evidence standard the assessing body treats as the currency, and on that question the two companies have taken opposite positions. A reader can stop here with the full picture. The sections below are the detail.
Ten weeks, four approvals, one population
On 22 May the FDA approved datopotamab deruxtecan for unresectable or metastatic triple-negative breast cancer in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy, on TROPION-Breast02, a 644-patient trial. Thirty-three days later the FDA approved sacituzumab govitecan in two first-line indications: as a single agent in the same immunotherapy-ineligible population on ASCENT-03, a 558-patient trial, and with pembrolizumab in PD-L1-positive disease on ASCENT-04.
Europe ran the same sequence in reverse order. The European Commission cleared Trodelvy first-line on 23 June, and Datroway on 31 July. By the start of August both agencies had licensed two conjugates into one treatment decision.
These are not loosely similar products. Both are directed at TROP2. Both deliver a topoisomerase-1 inhibitor payload, SN-38 in one case and DXd in the other. Both are given first-line to patients whose tumours do not express PD-L1 at qualifying levels or who cannot receive checkpoint inhibition for other reasons. For a formulary committee, that is the definition of a therapeutic class rather than a set of unique agents.
Approved first-line positions in metastatic triple-negative breast cancer as at 14 August 2026. Segment widths reflect the roughly seven in ten share of patients described as ineligible for checkpoint inhibition, not measured prevalence.
FDA and European Commission decisions as issued · Company releases · Compiled 14 August 2026
The two owners have already chosen opposite evidence standards
Datroway’s approvals rest on survival. TROPION-Breast02 reported median overall survival of 23.7 months against 18.7 for chemotherapy, a hazard ratio of 0.79 at p=0.0290, with progression-free survival of 10.8 against 5.6 months and response in 64% against 30%. The European approval was accompanied by an ESMO Category IA listing and a score of four out of five on the Magnitude of Clinical Benefit Scale.
Trodelvy’s first-line approvals rest on progression-free survival: a 38% reduction in the risk of progression or death as monotherapy in ASCENT-03, and 35% in combination in ASCENT-04, with median duration of response of 12.2 months against 7.2. Survival was not mature at approval, and ASCENT-03 allowed patients on chemotherapy to cross over to Trodelvy on progression, a patient-centred design that also makes a future survival difference harder to demonstrate.
Neither position is a weakness by regulatory standards, since both agencies licensed both drugs. But the companies are not treating them as equivalent. Daiichi Sankyo titled its European announcement around Datroway being the only TROP2-directed medicine with an overall survival benefit in this setting, and Ken Keller repeated the claim in the quote. Gilead’s own framing is that Trodelvy is the only approved conjugate in first-line disease across PD-L1 status, with more than 75,000 patients treated to date. One is arguing depth of evidence, the other breadth of label and installed experience.
A second entrant is worth more to a payer than a better first one
Reimbursement systems are built to compare. An appraisal needs a comparator, a reference price and a plausible alternative if terms are refused. A conjugate arriving alone in its indication denies all three, which is why this class has been able to hold price so consistently and why single-product appraisals in it have so often ended in prolonged standoffs rather than agreements.
The immunotherapy-ineligible first-line segment now supplies what was missing. Two products, one target, one payload class, one population, both licensed by both agencies inside ten weeks. For the first time an assessing body in this category can ask what the alternative costs, and a procurement function can put two suppliers in the same conversation.
What complicates it is that the evidence is asymmetric in a way that matters more to health technology assessment than to regulators. Bodies that weight overall survival heavily, and discount progression-free survival where crossover is present, will not treat these as interchangeable however similar the mechanisms look. That gap is where the negotiation will actually happen, and it is why the survival claim was put in a headline rather than a footnote.
Two things to watch. Whether any European assessment appraises the two together as a class rather than sequentially as separate submissions, since sequential appraisal preserves the monopoly logic that joint appraisal removes. And whether ASCENT-03 survival, when it reads out, is interpretable at all given the crossover, because if it is not, the comparative question will stay open while both drugs are already in use.